Rui Plácido1, Nuno Cortez-Dias2, Susana Robalo Martins2, Ana Gomes Almeida2, Carina Calisto3, Susana Gonçalves2, Malha Sadoune4, António Nunes Diogo2, Alexandre Mebazaa5, Fausto José Pinto2. 1. Cardiology Department, Santa Maria Hospital, Lisbon Academic Medical Centre, CCUL, Lisbon, Portugal. Electronic address: placidorui@gmail.com. 2. Cardiology Department, Santa Maria Hospital, Lisbon Academic Medical Centre, CCUL, Lisbon, Portugal. 3. Pathology Department, Santa Maria Hospital, Lisbon, Portugal. 4. UMR-S 942, INSERM, Paris, France. 5. UMR-S 942, INSERM, Paris, France; Department of Anesthesiology and Critical Care Medicine, Saint Louis Lariboisière University Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France.
Abstract
INTRODUCTION: Pulmonary hypertension (PH) covers a group of conditions characterized by an increase in pulmonary vascular resistance leading to right ventricular failure. Risk stratification is crucial for adequate prognostic and therapeutic assessment. However, the accuracy of conventional parameters is limited, especially biomarkers. OBJECTIVES: To determine the prognostic value of new biomarkers and their combination in a multi-biomarker approach to predict outcome in patients with PH. METHODS: In this prospective cohort study, PH patients underwent clinical, echocardiographic and laboratory assessment, including quantification of serum N-terminal pro-brain natriuretic peptide (NT-proBNP) and of the following new biomarkers: mid-regional pro-adrenomedullin (MR-proADM), copeptin, endothelin-1, mid-regional pro-atrial natriuretic peptide (MR-proANP) and soluble ST2 (sST2), the interleukin-33 receptor. The accuracy of the different parameters for predicting all-cause mortality and death or hospitalization of cardiac causes was determined. The prognostic value of a multi-biomarker score based on the tertile distribution of serum NT-proBNP, MR-proANP, renin and sST2 was compared to conventional markers. RESULTS: Forty-three patients (72.1% female, age 59±15 years) were included, most of whom (65.1%) had group 1 PH. During a median follow-up of 34 months, 26% of the patients died and 35% were hospitalized for cardiac causes. Atrial and ventricular dimensions and right ventricular fractional area change were prognostic predictors. Log NT-proBNP (HR: 31.14; 95% CI: 3.12-310.7; p=0.003) and renin (HR: 1.02; 95% CI: 1.005-1.038; p=0.009) were independent predictors of mortality. MR-proANP (HR: 1.008; 95% CI 1.004-1.011; p<0.001) and sST2 (HR: 1.005; 95% CI 1.001-1.009; p=0.04) were predictors of death or hospitalization. The prognostic value of the multi-biomarker score was higher than any of the conventional parameters, and enabled identification of risk groups (the high-risk group had three-year mortality of 77.8%). CONCLUSION: A multi-biomarker approach was superior for risk stratification to any single marker. A score that incorporates NT-proBNP, MR-proANP, renin and sST2 accurately identifies patients at low, intermediate and high risk.
INTRODUCTION:Pulmonary hypertension (PH) covers a group of conditions characterized by an increase in pulmonary vascular resistance leading to right ventricular failure. Risk stratification is crucial for adequate prognostic and therapeutic assessment. However, the accuracy of conventional parameters is limited, especially biomarkers. OBJECTIVES: To determine the prognostic value of new biomarkers and their combination in a multi-biomarker approach to predict outcome in patients with PH. METHODS: In this prospective cohort study, PH patients underwent clinical, echocardiographic and laboratory assessment, including quantification of serum N-terminal pro-brain natriuretic peptide (NT-proBNP) and of the following new biomarkers: mid-regional pro-adrenomedullin (MR-proADM), copeptin, endothelin-1, mid-regional pro-atrial natriuretic peptide (MR-proANP) and soluble ST2 (sST2), the interleukin-33 receptor. The accuracy of the different parameters for predicting all-cause mortality and death or hospitalization of cardiac causes was determined. The prognostic value of a multi-biomarker score based on the tertile distribution of serum NT-proBNP, MR-proANP, renin and sST2 was compared to conventional markers. RESULTS: Forty-three patients (72.1% female, age 59±15 years) were included, most of whom (65.1%) had group 1 PH. During a median follow-up of 34 months, 26% of the patients died and 35% were hospitalized for cardiac causes. Atrial and ventricular dimensions and right ventricular fractional area change were prognostic predictors. Log NT-proBNP (HR: 31.14; 95% CI: 3.12-310.7; p=0.003) and renin (HR: 1.02; 95% CI: 1.005-1.038; p=0.009) were independent predictors of mortality. MR-proANP (HR: 1.008; 95% CI 1.004-1.011; p<0.001) and sST2 (HR: 1.005; 95% CI 1.001-1.009; p=0.04) were predictors of death or hospitalization. The prognostic value of the multi-biomarker score was higher than any of the conventional parameters, and enabled identification of risk groups (the high-risk group had three-year mortality of 77.8%). CONCLUSION: A multi-biomarker approach was superior for risk stratification to any single marker. A score that incorporates NT-proBNP, MR-proANP, renin and sST2 accurately identifies patients at low, intermediate and high risk.
Authors: Catherine E Simpson; Rachel L Damico; Paul M Hassoun; Lisa J Martin; Jun Yang; Melanie K Nies; R Dhananjay Vaidya; Stephanie Brandal; Michael W Pauciulo; Eric D Austin; D Dunbar Ivy; William C Nichols; Allen D Everett Journal: Chest Date: 2020-01-25 Impact factor: 9.410
Authors: Marta Banaszkiewicz; Arkadiusz Pietrasik; Michał Florczyk; Piotr Kędzierski; Michał Piłka; Rafał Mańczak; Janusz Kochman; Grzegorz Opolski; Adam Torbicki; Marcin Kurzyna; Szymon Darocha Journal: Diagnostics (Basel) Date: 2021-01-16
Authors: Steffen D Kriechbaum; Julia M Vietheer; Christoph B Wiedenroth; Felix Rudolph; Marta Barde; Jan-Sebastian Wolter; Moritz Haas; Ulrich Fischer-Rasokat; Maren Weferling; Andreas Rolf; Christian W Hamm; Eckhard Mayer; Stefan Guth; Till Keller; Fritz C Roller; Christoph Liebetrau Journal: Pulm Circ Date: 2021-12-10 Impact factor: 3.017
Authors: King Sum Luk; Christina Ip; Meng-Qi Gong; Sunny Hei Wong; William Kk Wu; Mei Dong; Guang-Ping Li; Ka Pang Chan; Yi-Mei Du; Tong Liu; Martin Cs Wong; David Shu Cheong Hui; Gary Tse Journal: J Geriatr Cardiol Date: 2017-12 Impact factor: 3.327
Authors: Laurie W Geenen; Vivan J M Baggen; Robert M Kauling; Thomas Koudstaal; Karin A Boomars; Eric Boersma; Jolien W Roos-Hesselink; Annemien E van den Bosch Journal: J Clin Med Date: 2019-09-20 Impact factor: 4.241